Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX
Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX
复制标题
DOI：
10.1245/s10434-010-0972-9
复制
发表时间：
2010-08-01
影响因子：
3.7
通讯作者：
Gruenberger, Thomas
中科院分区：
文献类型：
--
作者：
Klinger, Markus;Tamandl, Dietmar;Gruenberger, Thomas
结直肠癌肝转移对化疗的组织学反应可以根据肿瘤消退的程度进行分级。关于贝伐单抗（如果除氟嘧啶和奥沙利铂之外）对肿瘤消退及其对临床结果的影响的影响的知识是有限的。对 2 项前瞻性非随机试验（氟嘧啶和奥沙利铂 +/- A 贝伐单抗）患者切除的肝转移进行了回顾性分析。根据已建立的结直肠癌肝转移肿瘤消退分级来分析组织学反应。肿瘤消退等级 (TRG) 与无进展生存期和总生存期相关。贝伐单抗显着改善化疗后的肿瘤消退。组织学反应的改善转化为无进展生存期和总生存期的显着延长。根据肿瘤消退等级对组织学反应进行分类可以预测结直肠癌肝转移患者的结果。肿瘤消退分级提供了标准化的病理反应评估，可以根据该评估前瞻性评估化疗（包括生物制剂）的放射学反应。
Histological response of colorectal cancer liver metastases to chemotherapy may be graded based on the extent of tumor regression. The knowledge about the effect of bevacizumab, if given in addition to fluoropyrimidines and oxaliplatin, on tumor regression and its consequences on clinical outcome is limited.Resected liver metastases from patients of 2 prospective nonrandomized trials (fluoropyrimidines and oxaliplatin +/- A bevacizumab) were analyzed retrospectively. Histological response was analyzed according to an established tumor regression grading for colorectal cancer liver metastases. Tumor regression grades (TRGs) were correlated to progression-free and overall survival.Bevacizumab improved tumor regression to chemotherapy significantly. Improvement in histological response was translated into a significant prolongation of progression-free and overall survival.Classifying histological response based on tumor regression grades qualifies to predict the outcome of patients with colorectal cancer liver metastases. Tumor regression grading provides a standardized pathological response evaluation, against which radiologic response on chemotherapy including biologicals can be prospectively evaluated.